



NEWS

WINTER 2010

IN THIS ISSUE

3

NEWS @ SRI:
Schulich Heart Program Research Day; New Interim Director in Cancer Research; Government Crowns Centre "Excellent"

- 4 CV: DR. JUAN CARLOS ZÚÑIGA-PFLÜCKER
- 6 TRAINEES' POST
- 7 APPLAUSE

Brain Scientists Give Premier a Glimpse Into the Future

By Stephanie Roberts

No crystal ball was needed to give Ontario Premier Dalton McGuinty and Minister of Research and Innovation Glen Murray a look into the future of treatment for brain disorders. Instead, brain scientists gave the politicians an exclusive tour of the S ground imaging research facility at Sunnybrook Research Institute (SRI). The premier and minister were shown how magnetic resonance (MR)-guided focused ultrasound works during a visit to Sunnybrook to announce the Ontario Brain Institute on November 15.

"Showing Premier McGuinty and Minister Murray that we are at the forefront of brain sciences innovation not only in Ontario, but indeed in all the world, was an honour," said **Dr. Michael Julius**, vice-president, research, Sunnybrook Health Sciences Centre. "This work has led to breakthroughs on which a whole new science is being built. It's important we showcase our leadership in this arena."

Focused ultrasound is a method of applying energy to tissue located deep inside the body to effect a therapeutic result. When paired with MR, it enables precise targeting of the area of interest, helps guide the treatment as it is being performed, and verifies that the treatment worked (or did not work). Magnetic resonance-guided focused ultrasound has many potential applications; some of the most encouraging are in the brain.

Dr. Kullervo Hynnen, director of imaging research at SRI, invented the focused ultrasound device for the brain, which was subsequently commercialized by Israeli company InSightec.



Premier Dalton McGuinty and Dr. Sandra Black

Hynnen was unable to host the tour, owing to an out-of-country commitment. In his stead, **Drs. Bojana Stefanovic, Sandra Black** and **Todd Mainprize** anchored the event.

Stefanovic, an imaging scientist at SRI, explained the physics behind the device to the premier and minister. She described how the device's multiple arrays solve the problem of skull beam distortion and enable the ultrasound to be focused precisely where desired. As the premier looked at the helmet-shaped device, she noted this innovation solves a longstanding problem of how to get into the brain without opening the cranium.

Continued on page 2

New Structure for SRI

Dr. Michael Julius, vice-president of research at Sunnybrook Health Sciences Centre, held a town hall on Thursday, December 16, to talk with faculty, staff and students about the new academic structure for Sunnybrook Research Institute (SRI). The existing framework of disciplines has been dissolved. In its place, Julius outlined three platforms that will define SRI's strategic areas of focus. They are biological sciences, physical sciences and evaluative clinical sciences. All scientists at SRI will now align with one of these three platforms.

Julius announced **Dr. Kullervo Hynynen** will be the director of physical sciences, and named **Dr. Don Redelmeier** as director of clinical evaluative sciences. Recruitment is ongoing for the director of biological sciences; in the interim, **Dr. Juan Carlos Zúñiga-Pflücker** will serve as director (see CV on page 4). The process of the restructuring will be gradual, with formal changes rolling out over the next few months.

A Fresh Look for the Web

In December, Sunnybrook Research Institute (SRI) unveiled a new website design and structure, which gives SRI its own virtual subsite and menu. Visitors to sunnybrook.ca can now move between the research, hospital and foundation sections by clicking their respective tabs at the top of each page.

The new subsite features a redesigned and much more functional landing page, and a correspondingly reconfigured site map. The site addresses the needs of external and internal users.

The front page prominently displays rotating images corresponding to stories or featured sections; our Centre for Research in Image-Guided Therapeutics occupies prime real estate on the upper right-hand side, for easy access to all the latest on it; and there is dedicated space for SRI news and stories, events, publications and media features. A jargon decoder helps break down chewy terms for visitors less familiar with research.

Administrators can with one click now get to the sections they use the most, like the staff directory or Clinical Studies Resource Centre. Trainees also have a section of direct links to pages they visit most often. There is also a "Staff Only" link at the bottom of the page, with direct links to SRI-specific tools such as webmail, Oracle calendar and research computing help.

See the new site at sunnybrook.ca/research.

Trial To Examine Effects of Antidiabetic Drug on Birth Outcomes

The Centre for Mother, Infant and Child Research at Sunnybrook Research Institute has launched a new clinical trial. "Metformin in Women with Type 2 Diabetes in Pregnancy" will sample 500 pregnant women with type 2 diabetes to investigate whether the oral drug metformin, used to treat type 2 diabetes, in addition to a normal insulin regimen, increases or decreases the incidence of adverse perinatal outcomes, such as pregnancy loss, preterm birth or birth injury.

For more information on this trial, contact mity@sunnybrook.ca.

Continued from page 1

Black, director of the Brain Sciences Research Program, spoke to the device's therapeutic potential for stroke and dementia. She noted how in stroke it shows great promise to dissolve blood clots and restore blood flow in minutes in patients who are having a stroke. She also explained how researchers at SRI are using focused ultrasound paired with microbubbles to disrupt the blood-brain barrier and then deliver drug or gene therapy to localized brain regions to stop the progression of Alzheimer's disease.

Mainprize, a neurosurgeon at Sunnybrook, capped the tour by showing MR-guided focused ultrasound in action, using a phantom. He explained how the feedback that MR provides during a procedure enables physicians to make adjustments during the procedure, and confirms that the treatment is working. Mainprize then revealed that a clinical trial to test MR-guided focused ultrasound to treat essential tremors, the most common movement disorder, is set to begin in early 2011, followed later in the year by a trial for brain tumours.

"We are extremely optimistic about this novel technology and all of the potential applications to better the lives of patients in Ontario," said Mainprize.

After thanking the researchers for the tour, McGuinty and Murray were whisked away to the McLaughlin auditorium, where the premier announced \$15 million in funding over three years to establish the Ontario Brain Institute. This virtual organization will bring together leading scientists in brain research from across the province.

The imaging research suite on S ground is part of SRI's Centre for Research in Image-Guided Therapeutics (CeRIGT), a \$160-million centre that is scheduled for completion in 2011. The imaging suite has two InSightec systems for clinical testing, one for high-frequency brain work; the other for low-frequency brain work. Sunnybrook Research Institute is the only place in the world that has two systems.

To read more about CeRIGT, visit: sunnybrook.ca/research, and click on the CeRIGT image in the upper right-hand corner.



Schulich Heart Program Research Day Doesn't Miss a Beat

On November 24, scientists in cardiovascular research gathered for the fifth annual Schulich Heart Program Research Day, sponsored by Sunnybrook Research Institute (SRI). More than 170 people attended the successful event.

"Year to year, the Schulich Heart Program is making great strides in achieving results, both clinically and academically. There is much to celebrate," said **Dr. Michael Julius**, vice-president, research, Sunnybrook Health Sciences Centre, in his welcoming address.

The day was devoted to unpacking issues in state-of-the-art cardiovascular disease management, via 16 sessions about cardiovascular imaging, emerging surgical and interventional methods, and vascular disease management. **Dr. Graham Wright**, director of the Schulich Heart Research Program at SRI, gave the opening and closing remarks, and outlined accomplishments as well as challenges in the field.

Invited keynote speakers were Dr. Michael Farkouh, scientist at St. Michael's Hospital, and staff physician and director of clinical trials in cardiology at the University Health Network and Mount Sinai Hospital, who discussed atherosclerosis imaging initiatives; and Dr. Thomas Marwick, staff cardiologist and head of cardiovascular imaging at the Cleveland Clinic in Ohio, who spoke on imaging myocardial dysfunction.

Odette Cancer Research Program Gets Interim Director

Sunnybrook Research Institute imaging scientist **Dr. Gregory Czarnota** was appointed interim director of the Odette Cancer Research Program on November 8.



Dr. Gregory Czarnota

Czarnota's research focuses on using ultrasound imaging and spectroscopy to detect cell death after chemotherapy and radiation therapy. A main aim is to distinguish tumours that are responding to therapy from those that are not, so that the latter may be treated with different chemotherapy regimens or with radiation sensitizers to improve outcomes. Over the last four years, he has received more than \$10 million in peer-reviewed funding, including, recently, a \$2.7 million grant from the Terry Fox Foundation and Canadian Institutes of Health Research.

In 2005, he was recruited as a clinician-scientist to the department of radiation oncology at the Odette Cancer Centre, having completed first his PhD in the department of medical biophysics at the University of Toronto, and then his medical training and residency at U of T in radiation oncology.

Government Crowns Centre "Excellent"

The Canadian government has awarded \$13.3 million to Sunnybrook Research Institute (SRI) and the University of Western Ontario (UWO) to establish the Centre for Imaging Technology Commercialization and Research, a federal Centre of Excellence for Commercialization and Research. Minister of Industry Tony Clement made the announcement December 6 in Ottawa.

The Centre for Imaging Technology Commercialization and Research will address barriers that prevent Canadian medical imaging companies from commercializing imaging technology.


"Our goal is to move ideas and inventions from the lab to the clinic to further support the health care community and to benefit patients," says **Dr. Martin Yaffe**, senior imaging scientist at SRI, and the project lead at SRI. Dr. Aaron Fenster is the centre's lead at UWO.



From left to right: **Dr. Chad Gaffield**, president of the Social Sciences and Humanities Research Council; **Dr. Aaron Fenster**, centre director of the Centre for Imaging Technology Commercialization and Research (CITCR); **Carol Richardson**, director of operations, CITCR; **Tony Clement**, minister of industry; **Dr. Martin Yaffe**, associate centre director, CITCR; **Dr. Ted Hewitt**, vice-president of research and international relations, University of Western Ontario; and **Dr. Suzanne Fortier**, chair of the NCE steering committee and president of the Natural Sciences and Engineering Research Council

The centre will help small and medium-sized medical imaging companies with the expertise, technical know-how and infrastructure they need to become internationally competitive. It will also promote training and investment by cultivating private-academic partnerships. Finally, the centre will help manage intellectual property to ensure that inventions are not lost, and to maximize the return on government investment in medical imaging innovation in Ontario and Canada.

Tool Kit: SOLiD 4 Next-Generation DNA Sequence Analyzer



Dr. Arun Seth (left) and Dr. Yutaka Amemiya (right) will study genomic variations in triple negative breast cancer

It took hundreds of labs 13 years to sequence a rough draft of the human genome. With the SOLiD 4 next-generation analyzer from Applied Biosystems, new to Sunnybrook Research Institute (SRI) as of December 2010, genomics facility manager **Dr. Yutaka Amemiya** can sequence a genome in less than one month. Moreover, the system offers new methods through which researchers can study genomic variations that produce systemic effects in disease and health.

Dr. Arun Seth, academic director of the genomics facility, will use the SOLiD 4 system to study triple negative breast cancer, an aggressive form of the disease for which there is no effective therapy. “To identify new targets, now we can comprehensively compare triple negative breast cancer cell genomes for genetic mutations. We have a unique mouse model for this disease, and can monitor tumour growth and metastasis relative to additional mutations in novel genes,” says Seth.

About two dozen researchers at SRI and around Ontario plan to use the system, which can generate 1.4 billion sequence reads per run and 33-fold coverage (overlap) of a human genome, enabling comparison of data from dozens of individuals.

“In future, high-speed sequencing of new types of genomes, for example, cancer cell and immune cell genomes from patient biopsies, will reveal new targets and therapeutic strategies and will be used in translational research and personalized treatments,” says Seth.

The SOLiD 4 system is worth \$720,000 and was funded by a Canada Foundation for Innovation and Ministry of Research and Innovation grant led by **Dr. Martin Yaffe**, on which Seth is a co-investigator. Yaffe is a senior imaging scientist at SRI.

CV: Dr. Juan Carlos Zúñiga-Pflücker



Bio basics: Inaugural interim director and senior scientist, biological sciences, SRI. Canada Research Chair in Developmental Immunology, and professor in the department of immunology, University of Toronto. Director of the Advanced Regenerative Tissue Engineering Centre based at SRI. Completed a B.Sc. in zoology at the University of Maryland, a PhD in genetics and immunology at George Washington University, and a postdoctoral

fellowship at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland.

Who will comprise SRI's new platform, biological sciences?

Any researcher who was doing biology will be part of the new platform. We'll have 28 scientists and 134 staff in total, including 67 graduate students and postdoctoral fellows. Our foci will include, though won't be limited to, stem cell biology, regenerative medicine, neurosciences, vascular biology and immunology. We're recruiting a director for the platform.

What qualities are you looking for in the incoming platform director?

We want a scientist who is a leader in his or her field, but who can reach out to a diverse community of biologists and bring them together—a stellar researcher with strong administrative experience and leadership ability. Also, it will be important that they appreciate the integrative nature of biological studies and their integral relationship to the clinical programs of the hospital.

What functions will the new director perform, day-to-day?

They will need to advocate for biological sciences at the institutional level, which means solving budget and space issues, and ensuring researchers can access cutting-edge infrastructure for their work. They'll coordinate and host forums where trainees and scientists can interact—meetings, seminars and retreats, for example. More broadly, they should encourage the integration of biological sciences with the clinical priorities of the hospital, and make funding agencies and donors aware of what we do, thus ensuring that support for this platform blossoms.

Why is biology important?

Biology is about the inner workings of the body at the fundamental, molecular and cellular level—how the systems function together, in health and disease. Without an understanding of biology, there is no understanding of how medicine can be improved and new remedies discovered.

PEOPLE @ SRI

Newly Appointed:

Dr. Andre Amaral, CE, TECC (associate scientist)
Dr. Elizabeth David, imaging, Cancer (associate scientist)
Dr. Fiona Webster, CE, MSK (associate scientist)

Moving Within SRI:

Dr. Isabelle Aubert, CIB, Brain Sciences (promoted to senior scientist)

Unique Research Facility Launches in Toronto and Thunder Bay

Focused ultrasound surgery centre will lead practice-changing clinical trials

Sunnybrook Health Sciences Centre and Thunder Bay Regional Health Sciences Centre announced the opening of the world's first dual-site magnetic resonance (MR)-guided focused ultrasound surgery centre on November 24.

The two sites participated via videoconference; Dr. Barry McLellan, president and CEO of Sunnybrook, presided as master of ceremonies in Toronto.

Minister of Health and Long-Term Care Deb Matthews, Minister of Transportation Kathleen Wynne and Bill Mauro, MPP for Thunder Bay-Atikokan, were honoured guests. Each spoke to a standing-room-only crowd about the importance of this new centre for advancing research that will become tomorrow's standard of care. Matthews lauded the centre as a model of regional collaboration.

Scientists at Sunnybrook Research Institute (SRI) will work with clinicians to test the use of MR-guided focused ultrasound surgery to ablate tumours. The technology works by pairing MR with high-intensity focused ultrasound to a target within the body, such as a tumour. The ultrasound energy is applied precisely to that spot, where it generates heat and destroys the tumour while sparing surrounding tissue. Magnetic resonance is used to plan, guide and evaluate the procedure.

The first clinical trials, one here and one in Thunder Bay, are investigating the use of MR-guided focused ultrasound technology (manufactured by Philips) to destroy uterine fibroids. Following will be clinical trials for bone metastases, recurrent breast cancer, head and neck cancer, and rectal cancer.

Dr. Kullervo Hynynen, director of imaging at Sunnybrook Research Institute, pioneered the MRI-guided focused ultrasound technology that is at the core of the centre's work. **Dr. Elizabeth David**, an interventional radiologist at Sunnybrook, is the principal investigator of the clinical trial for uterine fibroids.

Following the speeches, Hynynen and David, accompanied by McLellan and **Dr. Michael Julius**, vice-president of research at Sunnybrook, gave Matthews, Mauro and Wynne a tour of the suite and demonstrated how the Philips system works.

In Toronto, the facility is part of SRI's Centre for Research in Image-Guided Therapeutics, established with funding by the Canada Foundation for Innovation.




Deb Matthews, minister of health and long-term care, speaks with Dr. Barry McLellan about the focused ultrasound centre



Bill Mauro, MPP for Thunder Bay-Atikokan



Dr. Elizabeth David explains the treatment for uterine fibroids in the newly launched MR-guided focused ultrasound surgery centre. Listening are Kathleen Wynne, minister of transportation; Deb Matthews; and Bill Mauro



Guests enjoyed the live streaming from Thunder Bay. L to R: Dr. Elizabeth David; Dr. Kullervo Hynynen; Kathleen Wynne; Deb Matthews; Bill Mauro; and Dr. Michael Julius, vice-president of research, Sunnybrook



Dr. Kullervo Hynynen took the ministers on a tour of the MR-guided focused ultrasound facility in the Odette Cancer Centre at Sunnybrook

Trainees' Post


For Students and Postdocs

Exploring New Paths

Like all first-year PhD students, **Haoran Li** has a long academic journey ahead of him. However, unlike most students, Li's journey has already taken him a 15-hour airplane ride from his hometown of Chengdu, China.

Li, who arrived at the University of Toronto in September on a \$35,000 Connaught scholarship, is a student in the lab of **Dr. Burton Yang**, a senior scientist in the Odette Cancer Research Program at Sunnybrook Research Institute.

Here, he tells **Dilys Chan** about his path from clinical to laboratory research, his experience applying for a PhD in Canada and how it all relates to the teachings of ancient Chinese philosophy.



Before coming to Canada for his PhD, Haoran Li vacationed in Tibet. "I like to travel, so living here hasn't been so difficult. It's just another journey."

Why did you decide to study abroad rather than stay in China?

It's a tradition for Chinese students to study abroad after their graduation from university, or even as early as high school. Studying internationally gives you the chance to broaden your vision, meet different people and experience a different culture.

How did you end up at Sunnybrook Research Institute?

By chance—I applied to a few countries for my PhD: Germany, the UK and Canada. When I found out I was not only accepted, but that I got a scholarship, I was so happy I wanted to scream. The scholarship awarded a lot of money, and only 10 people at U of T received it. I'm really lucky.

Tell me about your application process.

Normally, to apply for a PhD, you send a couple of e-mails every day for months to professors you want to work with. But when I sent Dr. Yang my first e-mail, he replied quickly and agreed to admit me based on my CV. He wanted to form a research relationship with my university (Sun Yat-sen University), one of the top universities in Guangdong province. As well, a PhD student in his lab had just graduated, so he had grants and available space.

Tell me about your research.

Originally, we thought that genes—the code of life—were from DNA, RNA and that was it. But the human genome project found that humans don't have many more genes than mice do. So, why is it that human beings became the dominant species? This led researchers to think that maybe there are other things regulating genes, such as what our lab is studying: microRNA.

Recently, it has become apparent that microRNA regulates post-transcription of genes. Development of cancer may be tied to microRNA, so we want to understand the relationship for hints on how to treat cancer.

You used to study clinical medicine. Why focus on lab research now?

A Confucius saying comes to mind. He says that he who learns but does not think is lost, and he who thinks but does not learn is in great danger. For me, that means if I do clinical work without knowing the frontline of scientific research, I may lose direction. And if I do research without thinking about how to translate discoveries into clinical use, then my efforts will be in vain.

How's the adjustment from clinical work to lab research?

It's quite a jump. Before starting my PhD, my major was oncology and I treated cancer patients. I have a lot to learn. My cells are like my babies—I monitor them twice a day and keep them in a warm and healthy environment. But every day I find some dying! It can be so disappointing.

On the other hand, as an oncologist it was hard to see cancer patients get worse day by day. In the lab, your cells may die, but you can replace them and try again—although there is pressure to publish.

Do you have plans after you finish your PhD?

It's so far ahead, but if there's a chance, I would like to be a clinician-scientist and combine my clinical work with my research work.

Applause

Dr. John Ebos Hot Paper in Biology

Dr. John Ebos, a postdoctoral fellow in the lab of senior scientist **Dr. Robert Kerbel**, is the lead author of the second-most-cited biology paper published in the past two years, according to the “Hot Papers” database maintained by Thomson Reuters. The journal *Cancer Cell* published the paper, “Accelerated Metastasis After Short-Term Treatment With a Potent Inhibitor of Tumor Angiogenesis,” on March 3, 2009. Other researchers have cited the paper 134 times in the 19 months following its publication.



Dr. Michael Julius Israel Cancer Research Fund

Dr. Michael Julius, vice-president of research at Sunnybrook Health Sciences Centre, received a Man of Distinction 2010 award from the Israel Cancer Research Fund in recognition of his contributions to the field of immunology. Julius was commended for his work toward understanding lymphocyte activation, and the cellular and molecular interactions culminating in protective immunity. This work has led to numerous breakthroughs in the field, and has formed a foundation on which many other immunologists worldwide are building.



Dr. Graham Wright Canada Research Chair in Imaging for Cardiovascular Therapeutics

Dr. Graham Wright, director of and senior scientist in the Schulich Heart Research Program at Sunnybrook Research Institute (SRI), has been awarded the Tier 1 Canada Research Chair in Imaging for Cardiovascular Therapeutics. The award guarantees \$1.4 million in salary over seven years. Wright is a professor of medical biophysics at the University of Toronto and a scientist in SRI's Centre for Research in Image-Guided Therapeutics.



Early in his career, Wright studied a functional magnetic resonance imaging (MRI) issue—oxygen levels in blood—and he pioneered the first method for noninvasive, in vivo measurement of blood oxygen. Clinicians are testing this technique in the diagnosis and assessment of heart conditions.

A logical evolution of this work is linking the powers of diagnostic imaging more closely with therapy. His research program has evolved toward imaging physiology precisely and rapidly within a procedure suite, in hopes of making more accurate treatment decisions and directly guiding cardiac interventions.

Dr. Ross Upshur Canada Research Chair in Primary Care Research

Dr. Ross Upshur, an associate scientist in clinical epidemiology, was awarded a renewal of his Tier 2 Canada Research Chair in Primary Care Research. His research involves creating knowledge to reform the primary health care system and responding directly to current challenges in providing primary health care.



Upshur has established a multidisciplinary research program that blends knowledge from epidemiology, ethics and clinical medicine. He is also the director of the Joint Centre for Bioethics and an associate professor in the departments of family and community medicine, and public health sciences at the University of Toronto.



Walker/Marshall Award Winner Keeps It All Balanced

Jelena Tomic, a PhD student in the lab of **Dr. David Spaner**, a molecular biologist in the Odette Cancer Research Program at Sunnybrook Research Institute, has won the Walker/Marshall Prize. Awarded by the University of Toronto's department of medical biophysics, the prize recognizes a student whose academic achievements, publication record and contribution to student life are outstanding. Tomic won \$1,000 and spoke at the annual departmental retreat.

“Jelena is highly deserving of this award,” said Spaner. “Her discovery and characterization of the variations in responsiveness of leukemia cells to immunoreceptor agonists are important contributions to our understanding of cancer biology. They indicate new therapeutic strategies that we anticipate will be tested in clinical trials in the next several years.”

Tomic has authored six papers in peer-reviewed journals while pursuing her doctorate. She is also highly involved in student life in the department of medical biophysics at U of T; she served as student council vice-president for four years and president from 2008 to 2009. “I’m glad that I was able to balance it all and persevere against obstacles,” says Tomic. “Once I was given a chance to do what I love most, I did it well.”

WHAT'S ON

January 7

Safety Seminar

10:30 a.m.–noon

Sunnybrook Health Sciences Centre
Room SG 22

January 31–February 1

**9th Annual Imaging Network
Ontario Symposium**

University of Toronto Residence
89 Chestnut Street
www.imagingnetworkontario.ca

February 17

**Innovation & Commercialization Seminar
Series: Grant Application Planning**

9:00 a.m.–noon

Faculty of Medicine, University of Toronto
Red Seminar Room, Centre for Cellular
Biomolecular Research

January 13

**Innovation & Commercialization Seminar
Series: The Innovation Process**

9:00 a.m.–noon

Faculty of Medicine, University of Toronto
Medical Sciences Building, Room 2173

February 7

12th Annual Health Care Data Symposium

Institute for Clinical Evaluative Sciences

9:00 a.m.–4:30 p.m.

Toronto Hilton Hotel
145 Richmond Street West
www.ices.on.ca

March 17

**Innovation & Commercialization Seminar
Series: Intellectual Property**

9:00 a.m.–noon

Faculty of Medicine, University of Toronto
Red Seminar Room, Centre for Cellular
Biomolecular Research

Editor: Stephanie Roberts

Contributors: Dilys Chan, Eleni Kanavas, Jim Oldfield

Photography: Doug Nicholson

Nexus is published by the office of communications, Sunnybrook Research Institute: www.sunnybrook.ca/research.
We welcome your suggestions. Please send them to Eleni Kanavas at eleni.kanavas@sri.utoronto.ca.

On November 15, 2010, at Sunnybrook Health Sciences Centre, Premier Dalton McGuinty announced \$15 million to establish the Ontario Brain Institute. While at Sunnybrook, he was given a tour of the imaging research facility at Sunnybrook Research Institute, where scientists are leading studies in magnetic resonance-guided focused ultrasound for brain disorders. For more on this event, read the cover story in this issue of *Nexus*.



From left to right: In SRI's imaging research facility are David Leslie, chair of the board, Sunnybrook; Glen Murray, minister of research and innovation; Dr. Barry McLellan, president and CEO, Sunnybrook; Dr. Michael Julius, vice-president of research, Sunnybrook; Premier Dalton McGuinty; Dr. Todd Mainprize, neurosurgeon, Sunnybrook; Dr. Bojana Stefanovic, scientist, SRI; Dr. Sandra Black, director of the Brain Sciences Research Program, Sunnybrook; Sandra and Joseph Rotman, philanthropists.